Designation of Carglumic Acid (Ucedane) as an orphan drug by Orpharma Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Australian Parliament, provides a framework for regulating therapeutic goods, including medicines, medical devices, and blood. The Act aims to ensure that therapeutic goods available in Australia are of acceptable quality, safety, and efficacy. One of the key problems the Act was introduced to address is the regulation of drugs that might otherwise remain unapproved or under-researched due to their niche application or low commercial viability. In line with this objective, the Therapeutic Goods Administration (TGA) was established to administer the Act. Under the authority granted by the Act, the TGA has the power to designate certain drugs as orphan drugs, which are intended for the treatment of rare medical conditions. The designation process aims to incentivise the development and availability of treatments for rare diseases by providing various benefits to sponsors, including priority assessment of applications and financial incentives. The designation of Carglumic acid (Ucedane) as an orphan drug on 11 October 2016 is an example of the TGA’s commitment to addressing the unmet medical needs of patients with rare conditions, such as hyperammonaemia due to N-acetylglutamate synthase deficiency and various organic acidaemias.

Scope and Application

The Therapeutic Goods Act 1989, under which this designation is made, applies to therapeutic goods, including medicines, medical devices, and blood products within Australia. This particular designation pertains to Carglumic acid (Ucedane), identifying it as an orphan drug specifically for the treatment of certain forms of hyperammonaemia. This legislative act falls under the purview of the Commonwealth of Australia and is administered by the Therapeutic Goods Administration (TGA). The scope of this designation includes ensuring that Carglumic acid (Ucedane) is recognised for its specific use in treating rare metabolic disorders such as N-acetylglutamate synthase deficiency and organic acidaemias, including isovaleric, methylmalonic, and propionic acidaemias. The geographic reach of this legislation is national, encompassing all states and territories of Australia. The designation does not specify exclusions or exemptions, but it is subject to the broader regulatory framework established under the Therapeutic Goods Act and the Therapeutic Goods Regulations 1990. The application of this Act can be further extended or modified through subordinate instruments as required by the TGA.

Key Provisions

The Therapeutic Goods Act 1989, as applied through the Therapeutic Goods Regulations 1990, includes provisions that allow the designation of certain medications as orphan drugs. Section 16J of the Regulations facilitates this process, enabling the designation of a drug intended to treat rare medical conditions. In this instance, Carglumic acid (Ucedane) has been designated as an orphan drug (Section 16J(2) of the Regulations) for the treatment of specific types of hyperammonaemia, namely hyperammonaemia due to N-acetylglutamate synthase primary deficiency and hyperammonaemia due to organic acidaemias such as isovaleric acidaemia, methylmalonic acidaemia, and propionic acidaemia. This designation is significant because it acknowledges the rarity of these conditions and the importance of providing effective treatment options for patients suffering from them. The designation of Carglumic acid (Ucedane) as an orphan drug imposes certain obligations on the parties involved. The sponsor of the drug, Orpharma Pty Ltd, must ensure that the drug is manufactured and supplied in accordance with the requirements set out in the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990. This includes adhering to Good Manufacturing Practice (GMP) standards and maintaining appropriate records and documentation. Additionally, the sponsor must ensure that the drug is supplied only to authorised healthcare professionals and that it is accompanied by the necessary labelling and information to ensure safe and effective use. Failure to comply with the obligations and requirements imposed by the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can result in serious consequences. Offences under the Act can lead to civil or criminal penalties, including fines and imprisonment. For example, supplying a therapeutic good that does not comply with the Act or the Regulations can result in a fine of up to $2,200,000 for a corporation and imprisonment for up to five years for an individual. Furthermore, the Therapeutic Goods Administration (TGA) has the authority to take enforcement actions such as product recalls, court proceedings, and the imposition of administrative penalties. These measures are in place to ensure that therapeutic goods are safe, of high quality, and effectively meet the needs of the Australian public.